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In this review, the authors summarize the developments in surface modification of cardiovascular
materials especially in author’s laboratory. The authors focus on three different strategies to
construct multifunctional surfaces including coimmobilization of various biomolecules on stent
surfaces, stem cell based therapy systems, and a single-molecule multipurpose modification strategy
in vascular interventional therapy. The roles of various molecules like heparin, gallic acid, various
aptamers, and nitric oxide are highlighted in the new strategies for developing cardiovascular stent
surfaces with novel functions including excellent hemocompatibility, inhibiting smooth muscle cells
proliferation, and native endothelium regeneration. The success of these multifunctional surfaces
provides the tremendous potential in designing the next generation of vascular stents. VC 2014
American Vacuum Society. [http://dx.doi.org/10.1116/1.4878719]
I. INTRODUCTION
The last half of the 20th century has witnessed the emer-
gence of the medical device/implant industry. To our delight,
the technological revolution in healthcare is growing rapidly,
and most advances were in the area of cardiovascular tech-
nology.1 However, according to the statistics published by
the world health organization in 2012, cardiovascular dis-
eases (CVDs) continue to present the leading cause of death
in modern society.2 The majority of the CVDs are related to a
process called atherosclerosis, which is a chronic inflamma-
tory disease marked by thickening, hardening, and stiffening
of the arterial walls and results in impaired blood circulation.3
Severe impairment of the blood flow traditionally required
intervention with bypass surgery. Vascular stents or grafts to
treat these coronary and peripheral artery diseases emerged
as minimal invasive alternatives to the surgery.
Coronary bypass surgery with patients’ own saphenous
vein or internal mammary artery has been the standard surgi-
cal treatment method to reestablish the blood flow in occluded
arteries.4 Actually, there are difficulties in harvesting
sufficient lengths of autologous vascular grafts. Synthetic vas-
cular grafts made of ePTFE (expanded polytetrafluoroethyl-
ene), PET (polyethylene terephthalate), PU (polyurethane),
for example, are also used to replace or bypass diseased
arteries. However, these materials, originally designed for
industrial applications are associated with significant rates of
restenosis and thrombosis.5 In addition to vascular grafts, cor-
onary stenting has developed as a valid alternative method to
prevent abrupt vessel closure and to achieve excellent angio-
graphic results. Vascular stents are small expandable tubes,
which are mounted onto a balloon catheter, inserted and
expanded at the narrowed section of the vessel, acting like a
stabilizing scaffold for the artery to maintain the patency of
the vessel in order to treat narrowed or weakened arteries in
the body. Despite of intensive research on improving vascular
stents, failure cases of the implants still exist. In-stent resteno-
sis (ISR), which results from intimal hyperplasia, frequently
happened to patients implanted with the first generation of
stents, the bare metal stents (BMS).6 Late stent thrombosis
(LST) is a major complication of the patients who received
implantation of the following generation of stents, the drug
eluting stents (DES).7 Recently, new concepts of vascular
stents like endothelial progenitor cell (EPC) capture stents
and biodegradable stents (BDS) have emerged. In the clinical
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studies of the Genous Stent (anti-CD34 antibody coated sur-
face, capturing EPCs), no acute or subacute stent thrombosis
was observed. But CD34-positive cells can differentiate into
various kinds of cells including inflammatory cells and vascu-
lar smooth muscle cells (SMCs) and thus these kinds of stents
increased the risks of ISR and LST as well.8 Another promis-
ing approach to overcome these limitations is the application
of biodegradable cardiovascular stents, which could be made
of both polymers (lactic acid,9 glycolic,10 caprolactone fami-
lies,11 etc.) and metals (Mg-based,12 Fe-based alloys,13 Zn-
based,14 etc.). However, the degradation time of polymers of
about 2 yr is too long, and the uncontrollable degradation rate
of magnesium within less than six month is too fast. There is
still a gap between the degradation periods of existing stents
and an ideal BDS degradation period, which is assumed to be
about 6–12 months.15 Furthermore, the corrosion products, for
example, lactic acid from poly(L-lactic acid) and Mg(OH)2
from magnesium alloys, significantly disturb the local envi-
ronment by pH shifts, osmotic changes, and unphysiologic ion
concentrations. Not all of these products underwent in depth
evaluation yet.
Despite the impressive progress in the design of novel
vascular stents, the pursuit of improving stent performance
through surface modification has not stopped. From the
BMS to DES, and from BDS to EPC capture stents, a large
number of novel vascular stent models have been developed,
focusing on new stent platforms, new bioactive coatings,
novel functional surfaces, and new drug combinations. This
article reports the recent research and applications of devel-
oping cardiovascular stent surfaces with novel functions
emerged, especially in the author’s laboratory. The objective
of our work is to apply surface modification techniques for
making cardiovascular stents to smart interventional devices,
which can regulate blood-implant responses in a spatiotem-
poral way, accelerate the repair of endothelium and promote
the healing of atherosclerosis.
II. BASIC REQUIREMENTS OFAN IDEAL
VASCULAR STENT
Currently, numerous reviews have discussed the basic
characteristics of vascular stents. Mechanical factors and bi-
ological factors are the main considerations in the design of
a new stent.16 Mechanical factors include the following
aspects: (1) both flexibility and strength are basic require-
ments to the substrate material. On one hand, it must be
delivered to the small diameter atherosclerotic arteries; on
the other hand, the substrate material should overcome the
forces imposed by the vessel wall, avoid the recoil, and sup-
port vascular remodeling. That is why novel alloys, for
example, Co-Cr and Pt-Cr alloys, become popular instead of
316L stainless steel (SS). Hand in hand with the mechanical
properties of the material goes the stent geometry, the thick-
ness of the struts, the connections and the surface area.17 (2)
Magnetic resonance imaging (MRI) compatibility: With the
assistance of MRI, doctors are able to track the location of
the stent and inflate the balloon through a catheter to expand
the narrowed vessel wall. Taking Pt-Ir alloys for instance, it
shows excellent radiopacity and also present a reduction in
both thrombosis and neointimal proliferation. However, we
have to face the problem of poor mechanical properties.18
Fortunately, with the development of material science and
commercially available finite element solver, novel stent
designs that match the substrate materials with the strut for
better behavior has been a basic technique in almost all of
the medical device companies.
However, it must be admitted that the advanced substrate
materials only could provide a limited improvement of the
stent performance. There are generally compromises between
the optimized mechanical properties and the complex require-
ments of the bioenvironment. Consequently, sophisticated
surface engineering has to be performed to address all the bi-
ological circumstances.19 (1) Hemocompatibility and antith-
rombotic properties: Materials surface should be blood
compatible and able to resist plasma protein adsorption and
denaturation, platelets adhesion and activation, blood coagu-
lation factor activation, etc. (2) Suppression of SMCs:
Excessive proliferation of SMCs is one of the initial factors
in an atherosclerotic plaque. Also the SMCs associated neoin-
timal hyperplasia is the main failure mechanism of BMS. (3)
Endothelial cell-friendly microenvironment: Considering the
significant role of the native endothelium in healing after the
trauma of stent placement and as an antithrombotic surface,
the ideal stent surface should actively promote endothelializa-
tion.20 Based on this point, the concept of EPC capture stents
aiming at rapid endothelialization has raised up and plenty of
animal experiments and clinical tests are under evaluation.
The selectively targeted influence of the various vascular
cells [platelets, SMCs, endothelial cells (ECs), EPCs] by the
stent surface, however, is an ongoing and challenging task in
surface engineering science.
A. Surface functionalization strategies for improving
hemocompatibility
Blood–biomaterial interfacial events are considered as the
key point when evaluating the efficiency of a stent.21
Immediately after exposure of the stent to the blood, plasma
proteins adsorb to the surface of this foreign material and
undergo conformational changes. Blood platelets respond to
these external stimuli, especially to denatured fibrinogen on
the surface by adhesion, aggregation, and conversion to a
procoagulant state. In addition, the contact phase system
(factor XII and kallikrein) of the intrinsic pathway coagula-
tion cascade becomes activated, and the further progress of
the coagulation is propagated by the activated platelets.22
Afterwards, the activation and aggregation of platelets and
mononuclear cells and the generated fibrin form a stable
thrombus and narrow the blood vessel further.23 From this
point, limited hemocompatibility of DES substrate can lead
to ISR after the degradation of drug-loaded coating and
strongly contributes to the failure of these devices.
Surface modification techniques have been applied very
early to improve the hemocompatibility of the stents.24 The
029017-2 Qi et al.: New strategies for developing cardiovascular stent surfaces 029017-2
Biointerphases, Vol. 9, No. 2, June 2014
key approaches to control blood component responses have
been utilized to prepare surfaces with superior hemocompat-
ibility, including inhibition of fibrinogen denaturation, inhi-
bition of platelet aggregation and activation, blocking of the
active catalytic site of thrombin, minimizing the complement
associated inflammatory reactions, etc.25
B. Surface functionalization for inhibiting smooth
muscle cell proliferation
Poor hemocompatibility is not the only reason for the fail-
ure of BMS. As stated above, ISR by neointimal hyperplasia
is the leading complication of BMS. This intimal thickening,
containing mainly SMCs, is a reaction of the vessel wall to
the injury of stent expansion. The migrating SMCs cover the
luminal surface of stent struts and often overgrowing them
and cause the restenosis. Yet, the origin of the intimal SMCs
remains controversial.26,27 In addition to the SMCs from the
artery’s media, also bone marrow derived smooth-muscle
progenitor cells may participate in neointimal formation af-
ter vascular injury.28 It has been suggested that toxic ions
released from the cobalt-alloy implants induce monocyte
costimulatory molecule expression and release of proinflam-
matory cytokines and this may be the cause of the neointimal
formation and the clinical failure of stents.29
For the prevention of ISR, a revolutionary stent design
DES that combines drugs or agents with the medical devices
has been developed. This kind of stent suppresses the devel-
opment of lumen restenosis by the release of paclitaxel or
sirolimus, both of which are antiproliferative drugs used in
the treatment of cancer. Since its arrival in 2003, DES has
transformed the practice of interventional cardiology by dras-
tically reducing the restenosis rate and the need for revascu-
larization.30 Unfortunately, these kinds of drugs also suppress
the growth of ECs and delay the re-endothelialization.
Besides, the polymer carrier like poly(ethylene-co-vinyl ace-
tate) and poly(n-butyl methacrylate) in the first generation
DES (CypherTM and TaxusTM), the delayed endothelializa-
tion also leads to extended exposure of the drug-eluting poly-
mer coating to blood with the risk of LST. Nowadays,
polymer-free DES and metallic DES with biodegradable
polymers have been shown to improve the long-term safety
and efficacy as well and new DES with thinner struts releas-
ing limus-family analogues from durable polymers have fur-
ther improved the clinical outcomes.31 However, also in the
case of polymer-free DES and biodegradable carrier coated
DES, a bare metal surface remains in contact with the vessel
wall and/or the blood. The poor bio/blood compatibility of
the bare substrate still can stimulate coagulation and cells
dysfunction, especially soluble ions like Cr, Ni, and Co ions
released into the tissue may induce adverse tissue reactions.
In order to overcome the shortcoming of the above men-
tioned stents, the corresponding author of this paper pro-
posed the concept of a “time sequence functional stent,”
which combines a poly(lactic-co-glycolic acid) (PLGA)-
rapamycin coating on a Ti-O coated metal stent substrate.
The biodegradable PLGA controls the release of rapamycin
and the subsequently exposed Ti-O film on the substrate
presents good hemocompatibility. In the acute stage, the
released drug plays a crucial role to suppress restenosis.
Then the drug carrier PLGA starts to degrade and the Ti-O
film with good thromboresistant properties is exposed to
blood; it suppresses blood coagulation and supports endothe-
lialization.32 In the late stage, the Ti-O film coating on the
stent also prevents the release of toxic elements from the
stent into the surrounding tissue and increases the long-term
biocompatibility. One year clinical results showed that the
restenosis rate and late thrombus events are significantly
lower than the reference DES controls.33
C. Construction of ECs friendly stent surface
At present, DES are very popular and considered as a
breakthrough in interventional cardiology. As a revolution-
ary medical device combining drug and stent, DES show
statistically lower rate of ISR than BMS.34 However, the
long-term safety of DES was questioned at the European
Society of Cardiology Congress in 2006, and subsequent,
studies reported that sirolimus or paclitaxel eluting stents
were associated with similar risks of death or myocardial in-
farction as compared to BMS.35 Late thrombosis has
emerged as a major concern for DES implanted patients and
those suffering from late DES thrombosis reminded us of the
importance of arterial endothelium healing. The recent clini-
cal results have elucidated that the complete endothelializa-
tion with ability of inhibiting SMCs’ proliferation is an
essential process for maintaining arterial health. The loss of
endothelium is indeed a precondition for arterial thickening
and restenosis. The drug released from DES inhibits both the
growth of SMCs and ECs, slowing down the process of ISR
but delaying the repair of endothelium. Actually, a healthy
endothelium normally provides an anticoagulant and antipro-
liferative surface, acting as an effective natural protection
against thrombosis.36
Nowadays, there is a development to design stent surfa-
ces, which support endothelialization better. There is search
for new drugs or molecules with selective cytotoxicity to
SMCs but not to ECs for the application in DES. Apart from
utilizing DES, improving stents without drug release, but
stable modified with ligands for ECs adhesion molecules and
EPCs capture molecule is another exciting and encouraging
approach. Perhaps, future DES designs based on drug devel-
opment will be guided more from the expertise of clinicians
and pharmaceutical experts. Surface engineers are much
more interested in the design of multifunctional surfaces
which satisfy all the requirements of an ideal vascular stent
to the greatest extent, typically via directing the cell develop-
ment using bioactive molecules.
III. NOVEL STRATEGIES IN CONSTRUCTING
MULTIFUNCTIONAL STENT SYSTEM
Since the success application of the Ti-O film based time
sequence functional stents in our laboratory, we have paid
more attention on new strategies for developing cardiovascular
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stent surfaces with novel functions in the recent years. In the
following part, we would like to review our attempts for devel-
oping cardiovascular stent surfaces with novel functions,
including our latest discoveries in three fields: (1) multifunc-
tion synergy by coimmobilization of biomolecules; (2) stem
cell based strategies applied on vascular stents; (3) realization
of multifuntionalization by single molecule based surface
modification.
A. Multifunction synergy by layer-by-layer
coimmobilized biomolecules
Multifunctional surfaces based on the coimmobilization
of two or more biomolecules with synergistic action are fre-
quently desired. At present, various techniques are available
for immobilization of biomolecules on vascular stent surfa-
ces including physical adsorption, monolayer self-assembly,
and layer-by-layer (LBL), functional groups mediated
anchoring and direct solution mixed covalent immobiliza-
tion. The method of electrostatic LBL assembly with a cati-
onic and an anionic polyelectrolyte, such as various growth
factors and other proteins has been widely applied to con-
struct a multifunctional surface.37 Aiming at constructing an
anticoagulant, endothelialization supporting or EPC captur-
ing surface, different polyelectrolytes, for example, heparin,
adhesion proteins, and antibodies were chosen to construct
the multifunction surface.
In the recent decade, many groups have adopted LBL to
construct multifunctional surfaces. In the field of cardiovas-
cular materials modification, this method is highly attractive,
as it can be applied also to complex shaped surfaces. In 2009,
Meng et al. alternatively deposited chitosan and heparin onto
a coronary stent to accelerate the re-endothelialization and
healing process after coronary stent deployment. The LBL
technique was confirmed to be easily applied onto DES sys-
tem and stable during sterilization and storage.38 With the
same strategy, Luan et al. chose soluble complement receptor
1 and heparin as the assembled molecules to construct a sur-
face that inhibits blood coagulation and complement activa-
tion and thus prolongs graft or stent survival.39 Recently,
categories of assembling molecules have extended varying
from the original proteins or charged polymers to novel drug-
loaded micelles or specific biomolecules like siRNA and
antibodies. In 2009, Kim et al. reported a multilayer for stent
system composed of anionic poly(lactic-co-glycolic acid)
grafted hyaluronic acid micelles encapsulating paclitaxel,
heparin, and PLL via an LBL fashion. The heparin and pacli-
taxel in suitable amount in the multilayer were readily con-
trolled for a sustained release and effectively inhibited the
proliferation of SMC.40 Lu et al. (2013) published their sys-
tematic results of ePTFE grafts coated with anti-CD133 func-
tionalized heparin/collagen multilayers. Histopathological
staining and scanning electron microscopy indicated that the
anti-CD133 antibody accelerated the attachment of vascular
endothelial cells onto the ePTFE grafts. They also empha-
sized that tailoring early rapid endothelialization had been
of great significance in designing novel vascular grafts or
stents.41 In the same year, hyaluronic acid/chitosan films with
incorporated small interfering RNA (siRNA) nanoplexes
were achieved by Wendel and Krastev groups.42 This stent
surface suggested the low adhesion of blood cells on the poly-
electrolyte multilayers, as it prevents thrombosis after stent-
ing. Gene eluting system might offer a powerful technique
for novel DES to prevent restenosis in the future.43
Fortunately, fabrication of multilayers by consecutive adsorp-
tion of polyanions and polycations provides a flexible plat-
form for alternative deposition of novel biomolecules for
tailored multifunction architecture.
Our group has been working on the construction of multi-
functional stent surfaces via LBL techniques for a few years.
Li et al. improved blood compatibility and endothelialization
utilizing heparin and fibronectin (Hep/Fn) LBL coimmobili-
zation. The effect of different pH conditions on the assem-
bling effect depending was investigated and compared with
covalent immobilization methods. All results suggested that
the coimmobilized films of Hep/Fn confer good antithrom-
botic properties and with good endothelialization.44,45 Also,
inflammatory responses of these modified samples were fur-
ther evaluated. The results showed that Hep/Fn modified tita-
nium revealed a lower inflammatory response than pristine
Ti, as determined by the release of the TNF-a, MCP-1 and
IL-1b from macrophages and endothelial cells seeded onto
the materials.46 Also extracellular matrix components such
as collagen,47 fibronectin,48 laminin and their derived pep-
tide sequences RGD, REDV, YIGSR, etc., were integrated
in together with heparin in LBL deposited coatings on tita-
nium surfaces, and these surfaces were shown to improve
EC adhesion and proliferation and enhance the hemocompat-
ibility. However, the detailed mechanism of multifunctional
synergy of heparin and adhesive proteins remains unclear,
which still needs further investigation.
B. Stem cell based strategies applied on vascular
stents
A novel strategy of in vivo/in situ endothelialization of
vascular implant for accelerating vessel repair after stent im-
plantation has been recently developed. Supporting the hom-
ing of stem cells or progenitor cells at the site of the injury,
accelerates endothelialization and presents a self-healing
system with accelerated repair of the damaged endothe-
lium.49 The responsible cell source for re-endothelialization,
the EPCs has been first described by Asahara in 1997.50 In
the recent decades, this small population of CD34þ circulat-
ing mononuclear cells derived from bone morrow gained
increasing interest, because of its capability to differentiate
into mature ECs and participate in therapeutic angiogenesis
in vivo.
1. Stem cell capture surface for rapid
endothelialization
In 2005, Genous stent received CE mark and became the
first commercial vascular stent applying an EPC-capture sys-
tem based on immobilized anti-CD34 antibodies.51 Despite
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absence of acute or subacute stent thrombosis or stenosis in
clinical trials, there appeared the possibility that the stent
also pilots smooth muscle progenitor cells, which cause neo-
intimal proliferation. Continuous improve of EPC capture
stents therefore is still a huge task for the stent designers.
Lin et al. applied LBL techniques to construct a coated anti-
CD34 functionalized heparin–collagen multilayer with good
results concerning in situ endothelialization and as a possible
solution against in-stent restenosis.52 Anti-CD34 antibodies
also were grafted on a titanium surface via oriented immobi-
lization techniques.53 This coated surface could promoted
EPC adhesion under static and flowing condition in vitro,
and induced rapid endothelialization of a stent in vivo.
Although these designs could ensure a sufficient amount of
CD34þ stem cells, the cells did not differentiate further to
endothelium. Taking this limitation into account, heparin,
CD34 antibody and vascular endothelium growth factor
(VEGF) were coimmobilized on the stent surface, striking the
balance of antithrombosis and effective ECs-promotion.54 As
shown in Fig. 1, avidin was absorbed onto titanium via elec-
trostatic interactions. Afterwards, biotinylated heparin and
Protein A were immobilized onto the avidin coated surface
through biotin–avidin system. Subsequently this layer was
used to immobilize the anti-CD34 antibody and VEGF,
respectively, which is based on the specific binding of protein
A and Fc segments of CD34 antibody and the specific affinity
of heparin and VEGF. It was concluded that a biofunctional
LBL on titanium, constructed by assembling the anti-CD34
antibody, VEGF, and heparin, significantly improves the en-
dothelialization and anticoagulation.
Even though these designs proved to be safe and effec-
tive, the success of this fascinating technique largely
depends on the selection of optimal target molecules on the
membrane of the EPC surface. Wendel et al. questioned that
the concept of EPC capture stents is hype or hope. The chal-
lenge is if the capture molecules bind even weakly to other
blood cells (e.g., platelets, monocytes, and neutrophils) or
plasma proteins (fibrinogen, etc.), this technique will fail.
The immobilized capture molecules will be immediately
covered by competing proteins or cells considering their sig-
nificantly higher concentration in the blood stream than
EPCs.55 In literature, numerous molecules for capturing
EPCs have been applied to achieve self-endothelialization of
blood-contacting materials including monoclonal antibodies,
selectins and their ligands, peptide or DNA aptamers, and
even magnetic molecules.56 In 2013, Lee et al. compared
endothelialization and neointima formation of two EPC cap-
ture stents with CD34þ antibodies or vascular endothelial-
cadherin, respectively, coated on BMS. The VE-cadherin
worked out as the more suitable target molecule than CD34
for EPC-capturing stents.57 Our group also has made
attempts on constructing EPC capture surface. Using the
FIG. 1. Fluorescent images of EPCs, which adhered under flow conditions on bare titanium (Ti) or SS surface, or on these metals functionalized with EPC-
capture peptide- or DNA-aptamers or anti-CD34 antibodies. The peptide aptamer was grafted via Schiff’s base reaction on a polydopamine coating, the DNA
aptamer via electrostatic adsorption onto a plasma polymerized allylamine coating and the antibody together with heparin and VEGF in an electrostatic layer-
by-layer deposition technique. Cell nuclei are stained blue (DAPI) and cytoplasma in green/red (Rhodamine).
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biotin-avidin system, a peptide aptamer(TPSLEQRTVYAK-
GGGC-K-Biotin) and bovine serum albumin (BSA) were
immobilized onto titanium via mussel-inspired dopamine
film as shown in Fig. 1 (unpublished data). In vivo experi-
ments showed that the aptamer and BSA coimmobilized sur-
face had only low antithrombogenic property but also
accelerated the self-endothelialization in situ. Another trial
was the immobilization of DNA aptamers to construct an
EPC-capture surface on a plasma polymerized allylamine
(PPAam) film. The modified samples captured more EPC
under a nonstatic conditions and present a cell friendly sur-
face for both EPCs’ and ECs’ proliferation (Fig. 1, unpub-
lished data). However, there are also limitations with this
design. Peptide or DNA aptamers that specifically bind to
EPC were obtained through an in vitro selection process
known as phase display58 and systematic evolution of
ligands by exponential enrichment,59 respectively. Their bio-
safety and biostability are still unknown because in vivo ani-
mal tests and long term evaluation have not been conducted
systematically. However, taking advantages of EPC-specific
molecules to utilize the self-healing system of the organism
by fishing EPC to the vascular lesion have brought a para-
digm change in surface modification concepts for in vivo en-
dothelialization. Our group continuously performs more
basic studies and animal tests to optimize the EPC capture
surface in order to develop a novel generation vascular stent
based on this principle.
2. Stem cells mediated vessel healing in multiple
dimensions
EPCs can be isolated and labeled by incubation with
superparamagnetic iron oxide (SPIO) particles via phagocy-
tosis processes. This method to capture and to retain mesen-
chymal stem cells or circulating EPCs at the vascular injury
site provides a novel approach to realize a targeted guidance
of the cells. Li et al. labeled EPCs with silica coated SPIO
nanoparticles and an applied exterior magnetic field to guide
it toward the ischemic region in a mouse model of middle
cerebral artery occlusion in vivo.60 Riegler et al. also demon-
strated that conjugation with SPIO nanoparticles does not
exhibit adverse effects on cell viability, differentiation, or
secretion patterns. The increase in stem cell retention
resulted in a decrease in the restenosis level three weeks af-
ter cell delivery.61 Hence, our group prepared polyethylene
glycol (PEG) and anti-CD34-coated magnetic nanoparticles
(MNPs) to guide stem cells to a target destination in vivo by
MNPs in a magnetic field. Hemolysis rate and clotting time
(APTT) were determined to ensure the safety of the applica-
tion in the cardiovascular system. The ability of nanopar-
ticles to target stem cells in vitro and the influence of the
magnetic field strength on the stem cells capture effect were
evaluated as well. The designed MNPs possessed good
hemocompatibility and specifically bound to stem cells
(Fig. 2). The suitable response to an external magnetic
field helped to deliver stem cells to the lesion sites.62
Inspired from Polyak group’s work,63 our synthetic magnetic
nanoparticles were applied to construct an EPC captured sur-
face under exterior magnetic field. Different from EPC-
binding device surfaces, CD34þ binding MNPs can harvest
enough EPCs from the whole blood and guide these cells to
the location of the stent implantation by an external mag-
netic field.
With the development of biodegradable vascular stents,
Fe-based alloys also gained interest.13 However, the low cor-
rosion rate and difficulty in biological surface modification
limit the application of these materials in vascular stent
design.15 MNP guidance of EPCs, the magnetic iron stent
may find a revival in the future. Rapid endothelialization on
an iron stent surface may be accomplished under a magnetic
field. MNP-labeled stem cells can be accumulated at the
magnetic iron surface to achieve a native endothelium layer.
At various time points, repeatedly fresh MNPs can be
injected into the body to capture regenerated stem cells to
the desired location. From this conceive, stem cells mediated
injured vessel healing in multiple dimensions (time-space
relationship) is achieved as a more efficient treatment.
C. Multifuntionalization by single molecule based
surface modification
Currently, multifunction surfaces become the goal of
novel stent designs. Nevertheless, realization of multifunc-
tion requires the cooperative work of multiple molecules.
More extended clinical evaluation of isolated and combined
hazards to the patients are necessary with these more com-
plex devices. Therefore, a single molecule with multiple
functions, i.e., endothelialization promotion, anticoagulant,
antiplatelet, SMC suppression, and remedying atherosclero-
sis, for immobilization on the stent surface was sought.
During few years’ exploration in our group, several promis-
ing molecules were identified and immobilized. For instance,
heparin, GA, and nitric oxide (NO) donor systems have been
successfully introduced.
1. Heparin associated multifunctional stent coatings
Heparin, a highly sulfated polysaccharide, was discovered
in 1959.64 It is known as an anticoagulant drug and interacts
with a wide range of proteins, chemokines, and growth fac-
tors, and these interactions are implicated in immunology,
physiological, pathological processes, and many other bio-
logical processes, such as tissue structuring and organization,
blood clotting, and cell growth.65 Figure 3 reveals the multi-
ple functions of heparin. As an anticoagulant polysaccharide,
heparin of 18 or greater saccharide units catalyzes the inter-
action of antithrombin and thrombin, leading to the forma-
tion of covalent thrombin–antithrombin complexes, and thus
exhibits anticoagulant activities. A pentasaccharide sequence
of heparin already is sufficient to inhibit the coagulation fac-
tor Xa. This knowledge has been used for long time to pro-
duce anticoagulant coatings on surfaces by immobilizing
heparin at high concentrations to a surface using various
methods,66 up to the recent development of feedback-
controlled, coagulation triggered heparin release systems.67
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Besides this, heparin inhibits platelet function and indu-
ces the expression of markers of contractile SMC phenotype
and thus reduces SMC proliferation, which is considered as
the major mechanism by which local heparin therapy inhibits
restenosis.68 Heparin also presents anti-inflammatory proper-
ties by inhibition of the complement cascade and promotes
endothelium regeneration in some cases. The possible princi-
ple is the high affinity of various growth factors and other
proteins with an anion binding site to heparin. However, the
mechanism by which heparin promotes human endothelial
cell growth is not clear yet.
In our group, a heparinized surface was constructed via
covalently immobilization or ionic adsorption to a PPAam
film to explore the role of the heparin immobilized surfaces
in the direction of ECs and SMCs fate and re-endothelializa-
tion.69 The results [Fig. 4(a)] suggest that ECs on the
Heparin-PPAam undergo the general adhesion processes of
substrate attachment, spreading, and cytoskeleton develop-
ment and then proliferation. In addition to EC, also the mor-
phology, proliferation, and viability of SMCs were analyzed.
The Heparin-PPAam surface can effectively inhibit cell ad-
hesion, survival, proliferation, and increase the level of
SMCs apoptosis [Fig. 4(b)]. We also noticed that the PPAam
surface covalently immobilized with 3.6 lg/cm2 heparin
exhibited reduced adhesion and proliferation of ECs com-
pared to bare PPAam but higher adhesion and proliferation
of ECs than on 316L SS. PPAam functionalized with only
0.28 lg/cm2 heparin in a noncovalent manner showed much
greater ability to enhance EC adhesion and proliferation than
the 316L SS as well as the control PPAam.70 Another hepari-
nized surface was constructed in our group by immobilizing
heparin/poly-L-lysine nanoparticles conjugated at different
pH onto a dopamine coated surface, where a heparin density
gradient on a surface was generated by immobilizing nano-
particles of different heparin: poly-L-lysine ratios.71 The AT
III binding quantity on this surface was significantly
enhanced, and APTT and TT coagulation times were pro-
longed, depending on the heparin density. Also, a low hepa-
rin density is sufficient to prevent platelet adhesion and
activation. Meanwhile, the biological compatibility evalua-
tion suggested that a high heparin density above 20 lg/cm2
was unsuitable for vascular cell proliferation and endothe-
lium regeneration, while low heparin density up to
3.5 lg/cm2 selectively prevented SMCs proliferation but
accelerated endothelialization. Therefore, the sensitivity of
vascular cells to the heparin density is very different, high
FIG. 2. Prussian blue stained stem cells incubated with different magnetic nanoparticles for one day. Incubation without magnetic field in (a)–(c). Incubation
for two days under the different magnetic field intensities of 100mT in (e), (g), and 300mT in (f), (h), (d) without magnetic field as control.
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FIG. 3. Multiple functions of heparin and associated biomolecules.
FIG. 4. (a) Immunofluorescent images of cytoskeletal actin for ECs on the 316L SS and Hep-PPAam surfaces after 2, 12 h, and 24 h of culture. (b)
Immunofluorescent images of a-SMA for HUASMCs on 316L SS, Hep-PPAam after one and three days of culture. (c) Schematic diagram of heparin adsorp-
tion on the protonated PPAam surface.
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heparin density suppresses the growth of all vascular cells,
while low heparin density selectively inhibits SMCs hyper-
plasia but promotes EPCs and ECs proliferation.
According to others’ previous report on heparinized surfa-
ces, for example, heparin-coated stent of Gong et al.72 and
heparin-doped polypyrrole by Stewart et al.,73 we conclude
that a material decorated with heparin, either bound in a
covalent or noncovalent manner, exhibits multiple functions
depending on the exposed heparin density. These results of
basic research promise a successful construction of multi-
functional heparinized surface which may reduce restenosis
and promote endothelialization, providing further concepts to
utilize heparin more effectively on surface modification of
vascular stents.
2. Gallic acid assisted surface modification of
vascular stents
GA (3,4,5-triphydroxyl-benzoic acid) is particularly
abundant in processed beverages such as red wines and
green teas. It is a polyphenyl natural product, which can be
obtained under acid hydrolysis of hydrolysable tannins.74 It
is a strong natural antioxidant and presents some therapeutic
properties including antitumoral, antibacterial, antiviral, and
anti-inflammatory activities as observed in previous stud-
ies.75 In addition, GA has been found to selectively induce
apoptotic cell death in SMCs but no cytotoxicity against nor-
mal ECs.76 Based on these considerations, we introduced
GA in multifunctional films in various studies.
Taking the pharmacological effect of GA into account,
the influence of different concentrations of GA on ECs and
SMCs was investigated through culture of single cell types
and coculture, and some systematic results are shown in
Fig. 5. The ratio of ECs to SMCs in coculture condition has
a significant rise for GA concentrations of 5 lg/ml. These
data indicate that GA exhibits a selective dose-dependent
effect on ECs and SMCs, which promotes the growth of
ECs, while inhibits the growth of SMCs. For the design of
novel DES, GA with a released concentration of 5lg/ml
may be a suitable candidate to be loaded in a polymer coat-
ing.77 Another distinguishing feature of GA is the content of
catechol groups which can adsorb on metal surfaces.
Inspired of mussel derived dopamine self-polymerization,
GA, and hexamethylenediamine (HD) were used to form a
film (GAHD) under alkaline conditions (Tris 10mM,
pH¼ 8.5). The possible copolymerization mechanism of GA
and HD has been elucidated and results of biocompatibility
evaluation of GAHD film have been reported in 2013 (Fig.
6). It shows the immobilization strategy of heparin, laminin,
or fibronectin on the film with the coexistence of multiple
functional groups.78 Except of these adhesive proteins, anti-
CD34 antibodies and VEGF were also coimmobilized onto
the GA modified PPAam surface. Cell culture results indi-
cated significant enhancement in capturing EPCs and the
proliferation of ECs.79 To our delight, the GA-involved mul-
tifunctional coating shows a huge potential in tailoring the
desired interfacial properties onto a wide range of materials.
It selectively induces SMCs apoptosis but supports ECs
growth, suggesting a promising application for the design of
an ideal multifunctional vascular stent that is able to address
the issues of re-endothelialization and restenosis.80
3. Nitric oxide signal mediated stent design with
multifunctional surface
NO is a signaling molecule that plays a pivotal role in the
diagnosis, treatment, and prevention of life threatening car-
diovascular disorders such as coronary artery disease, essen-
tial hypertension, stroke, vascular complications of diabetes,
and related diseases.81 This cell signaling molecule that was
first discovered in the 1980s and once as endothelium-
derived relaxing factor it is constitutively and inducibly
expressed from ECs through enzymatic conversion of L-argi-
nine by various nitric oxide synthases (NOS).82 It has been
the subject of significant research not only in the basic scien-
ces, but also in applied sciences such as the biomaterials
field.83,84 As a star molecule in the cardiovascular system,
NO released from healthy endothelium simultaneously pos-
sesses anticoagulant,85 antiproliferative86 properties and has
the ability to promote the regeneration of healthy endothe-
lium87 (Fig. 7). Even in other cases, NO-delivery platform
present antibacterial properties88 and accelerate wound
FIG. 5. (a) Ratio of ECs and SMCs in cell numbers and cell area coverage in coculture after one day in medium containing GA. (b) Fluorescence micrographs
of EC (green) and SMC (orange). Scale bar is 100lm.
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healing process.89 Also, it plays a critical role in regulating
immune responses90 and inducing differentiation of stem
cells.91 These unique advantages make NO a very promising
molecule in the design of an ideal vascular stent.
Over the past few years, researchers (typically Meyerhoff
group) have been devoting themselves on the development
of efficient NO-releasing and -generating materials for clini-
cal therapies. Unique strategies for designing NO releasing
materials have been widely reviewed.92 Micelle, nanopar-
ticles, or dendrimers were synthesized with NO donors such
as S-nitrosothiols. Polysaccharide-based, metal complex-
based, heparin combined, and adhesive protein-combined
surface were also reported. These NO-donors type, particle-
type, and coating platforms present multiple biological func-
tions. However, there still exist some limitations of this kind
of material. A great challenge lies in the fabrication of cardi-
ovascular biomaterials while accommodating NO donors
due to their reactivity, nature, instability during storage, and
leaching of toxic byproducts.93 To overcome the present lim-
itations, recent strategies focus on transition metal-ions
FIG. 6. (a) Chemical structures and functional groups on polymerized GA and HD films. B) Fluorescence image of GAHD (blank). (c) Distribution of laminin
(green) and fibronectin (red) coconjugated to the GAHD surface via Schiff base reaction and carbodiimide chemistry, respectively. (d) Quantization of Fn and
Ln immobilized on Fn-GAHD and Ln-GAHD samples.
FIG. 7. Nitric oxide’s role in the vascular endothelium and its effects on cellular activities.
029017-10 Qi et al.: New strategies for developing cardiovascular stent surfaces 029017-10
Biointerphases, Vol. 9, No. 2, June 2014
mediated catalysis (Cu2þ, Fe2þ, Hg2þ, Agþ, organosele-
nium/tellurium compounds, or cystamine) to generate NO
from endogenous NO donor-RSNOs via specific glutathione
peroxidase(GPx)-like catalytic activity reactions.94,95 The
catalytic NO generation strategy was adopted to construct
multifunctional surfaces. The main reason is the expected
long-term release of NO via an endogenous NO donor
improves the stent performance.
In 2010, our group has taken an attempt on immobilizing
selenocystamine onto the Ti-O film to prepare a NO-
generation surface.96 Briefly, Ti-O was deposited onto 316L
SS via unbalanced magnetron sputtering. Multilayers of
polydopamine were grafted to the TiO2 surface by immer-
sion of the substrates in a 2mg/ml dopamine solution. The
subsequent oxidation process depends on the reaction of
amine groups of the selenocystamine(SeCys) via schiff base
reaction and Michael addition [Fig. 8(a)]. This SeCys modi-
fied surface presents GPx-like activity and catalytically gen-
erates NO with a rate of about 1 1010mol cm2 min1,
which approaches the normal NO synthesis and release from
healthy endothelial cells.97 Through the release of NO, the
modified surface remarkably inhibited the adhesion of plate-
lets and SMCs. In addition, it inhibited collagen-induced
platelet activation and aggregation. The increase of the intra-
cellular cGMP concentration confirmed that these phenom-
ena were due to NO specific signaling in platelets and SMCs
[Figs. 8(b) and 8(c)]. SeCys immobilized stents were
implanted into canine femoral arteries and the two months
in vivo implantation results showed significantly inhibited
intimal hyperplasia [Fig. 8(d)], suggesting the great promise
of the NO-releasing stent surface for cardiovascular therapy.
The NO-generating coatings therefore are also very promis-
ing candidates for a new generation of stents due to their ver-
satile abilities to improve hemocompatibility, enhance
endothelialization, inhibit SMC proliferation combined with
the potential biological functions of NO generation in
immune response, antibacterial behavior, inflammation pre-
vention, and healing atherosclerosis. Current and future
FIG. 8. (a) Schematic diagram of SeCys immobilization on polydopamine modified surface (TiO-SeCys). (b) cGMP concentration of platelets and SMCs on
Ti-O film and Ti-O-SeCys samples. (c) Platelets and SMCs adhesion on Ti-O film and Ti-O-SeCys samples. The unactived state platelets and absent adhesion
of SMCs on the Ti-O-SeCys samples are shown. (d) Optical photographs of the cross section slices of canine femoral arteries with SeCys functionalized (TiO-
SeCys) and control (SS) stents. The circle shows the differences in intimal hyperplasia. In the detail magnifications, lumen loss can be easily recognized in the
control but TiO-SeCys also keeps patent after two months.
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research on constructing NO releasing surfaces especially
stent surfaces will undoubtedly attract scientists, engineers,
and clinicians the opportunity to make significant advances
in the treatment and prevention of life threatening cardiovas-
cular disorders such as atherosclerosis.98
However, an ideal stent surface that could address all the
problems does not exist. For each method of multifunctional
surfaces, the specific disadvantages and limitations should
be carefully considered. Since most of the presented results
are based on in vitro or animal in vivo studies, few designs
have undergone the clinical evaluation yet. It has not been
proven so far, that the multifunctional surface performs well
in a complex biological environment. For example, the bio-
stability of the immobilized molecules is a crucial point
especially under long-term interactions with various
enzymes or other specific molecules. In the case of NO
releasing systems, the sufficiency of the NO-donor loading is
unclear, or a possible block of the catalytic reaction sites
(e.g., biomimetic organoselenium catalyst) can provide chal-
lenges in the designing of this surface type. MNPs-assisted
stem cell delivery system might avoid the above mentioned
disadvantages. Yet, cellular uptake, intracellular trafficking,
and cytotoxicity of MNPs as a matter of particle size await
further investigation. Also, as the MNPs get systemic distri-
bution, the biosafety of MNPs concerning other vital organs
needs to be evaluated.99 Thus, there is still a long way before
application of these strategies in future stents.
IV. CONCLUSION
With the objective of developing an innovative cardiovas-
cular stent surface to simultaneously improve hemocompati-
bility, endothelialization, and antiproliferative properties,
multifunctional surfaces were constructed in the author’s
group via different techniques. Tailoring BMS, DES, and
EPC capture stents, different molecules including heparin,
gallic acid, and various aptamers became our candidates for
novel stent designs. The systematic evaluation in vitro and
in vivo encouraged us to deeper exploration of these stent
models, and further basic experiments, animal tests, and clin-
ical trials need to be carried out. Also, we are looking for-
ward to the applications of nitric oxide releasing or
generating coatings in an ideal stent design, which presents a
huge potential in the cardiovascular system. Moreover, there
even exists the possibility of healing atherosclerosis due to
the diverse functions of nitric oxide. However, despite exten-
sive research to vascular stent for endothelium regenerative
purposes, not many biofunctionalized stents have been suc-
cessfully translated into the clinic. There are difficulties in
combining multiple signals to satisfy the microenvironment
where stent behaviors, which result in the unsuccessful
application in clinic. Therefore, the multifunctional stent sur-
face involved physical, biological, and chemical properties
need to be integrated and tuned for better control the differ-
ent processes of endothelium healing. We believe that our
various multifunctional stent surfaces will present good bio-
compatibility in the ongoing in vivo animal tests and enter
clinical trials in the near future. Scientists will spare no effort
on improving stent properties, providing systematic evalua-
tion of novel stents combining advanced surface modifica-
tion equipment and cellular or molecular biological
techniques and also in the same time, greatly enhance the
safety, cost-effectiveness, and efficacy of vascular stent in
applications of cardiovascular tissue regeneration and even
promote atherosclerosis healing.
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